Vtama pharmaceutical product tube
Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a treatment for plaque psoriasis.

HRSA Posts Two Drug Manufacturer Notices to 340B Entities

Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis.

The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered entities last week. The company, a subsidiary of Roivant Sciences, began selling Vtama in May 2022. It said it discovered that some entities may have bought Vtama at wholesaler acquisition price rather than at the 340B ceiling price from Q2 2022 through Q1 2023.

Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis. The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered […]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer